



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

May 28, 2025

To,

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001  
**Scrip Code: 543434**

National Stock Exchange of India Limited  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex  
Bandra (E), Mumbai - 400 051  
**NSE Symbol: SUPRIYA**

Dear Sir/Madam,

**Subject: Press Release- Audited Financial Results for the quarter and year ended March 31, 2025**

The Board of Directors of the Company at their Meeting held on May 27, 2025 has inter alia, considered and approved the Audited Financial Results for the quarter and year ended March 31, 2025.

Please find attached the Press Release regarding the Audited Financial Results of the Company for the quarter and year ended March 31, 2025.

Kindly take the same on record.

Thanking you,

**For Supriya Lifescience Limited**

**Prachi Sathe**  
**Company Secretary & Compliance Officer**

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website:  
[www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



## SUPRIYA LIFESCIENCE LTD.

### Press Release for immediate distribution

## **Supriya Lifescience Delivers Record-Breaking FY25 with 22% Revenue Growth**

*The Company's Q4 PAT Rises 38.4%, Backed by 16.4% Revenue Growth and Expansion in EBITDA Margin*

**Mumbai, 29th May 2025:** The unaudited financial statements for the quarter and full year ended March 31, 2025, have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 86 countries across the globe.

### **Key Consolidated Yearly Financial Highlights:**

Particulars	FY25	FY24
Revenues (in Rs Cr)	696.48	570.37
EBITDA (in Rs Cr)	260.80	172.98
EBITDA Margin	37.4%	30.3%
PAT (in Rs Cr)	187.96	119.11
PAT Margin	27.0%	20.9%
Quarterly EPS (in Rs)	23.35	14.80

### **Key Highlights for FY25:**

In FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 22% year-over-year increase, reaching Rs. 696.48 crore compared to Rs. 570.37 crore in FY24.

EBITDA for FY25 stood at Rs. 260.80 crore, with an EBITDA Margin of 37.4 %, as opposed to an EBITDA of Rs. 172.98 crore in FY24 with an EBITDA margin of 30.3%. This marks an improvement of 712 bps YoY.

Profit after Tax for FY25 stood at Rs. 187.96 crore, with a growth of 57.8% compared to Rs. 119.11 crore in FY24.

The PAT Margin stood at 27.0% in FY25, compared to 20.9% in FY24.

**Key Consolidated Q4 Financial Highlights:**

Particulars	Q4 FY25	Q4 FY24
Revenues (in Rs Cr)	184.11	158.18
EBITDA (in Rs Cr)	67.58	55.5
EBITDA Margin	36.7%	35.1%
PAT (in Rs Cr)	50.38	36.40
PAT Margin	27.4%	23.0%
Quarterly EPS (in Rs)	6.29	4.59

**Key Highlights for Q4 FY25:**

In the fourth quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 16.4 % year-over-year increase, reaching Rs. 184.11 crore compared to Rs. 158.18 crore in Q4 FY24.

EBITDA for Q4 FY25 stood at Rs. 67.58 crore, with an EBITDA Margin of 36.7 %, as opposed to an EBITDA of Rs. 55.5 crore in Q4 FY24 with an EBITDA margin of 35.1%. This marks an improvement of 162 bps YoY.

Profit after Tax for Q4 FY25 stood at Rs. 50.38 crore, with a growth of 38.4% compared to Rs. 36.40 crore in Q4 FY24.

The PAT Margin stood at 27.4% in Q4 FY25, compared to 23.0% in Q4 FY24.

**Dr. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience Ltd,** commenting on the results, said, *"FY25 has been a landmark year for Supriya Lifescience, reflecting the strength of our diversified product portfolio, resilient global operations, and consistent focus on operational excellence. We achieved our highest-ever annual revenue of **Rs. 697 crore**, up **22% year-on-year**, and delivered an EBITDA of **Rs. 261 crore** with a robust margin of **37.4%**. In Q4FY25, revenue grew by **16.4%** to **Rs. 184.11 crore**, while PAT rose by **38.4%** to **Rs. 50.38 crore**, supported by improved margins. Our strategic focus*

*on high-value therapeutic segments, deeper penetration in regulated markets, and strengthened backward integration continue to drive our performance. We remain committed to building on this momentum to deliver sustainable growth, foster innovation, and create long-term value for all stakeholders.”*

.....

**Disclaimer Statements** in this “Document” describing the company’s objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be “forward-looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

**About Supriya Lifescience Ltd.:**

Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company's primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.

**For more details, contact:**

**Abhishek Chawande:** [Abhishek.Chawande@dentsu.com](mailto:Abhishek.Chawande@dentsu.com) | 9664516774

**Sanjukta Ghadge :** [Sanjukta.ghadge@dentsu.com](mailto:Sanjukta.ghadge@dentsu.com) | 98926 89895